Summary
Federal Circuit affirms award of 50% of gross margin, finding that, even though the entire market value rule is not per se inapplicable in the pharmaceutical context, it does not apply in this case because patents cover the entire infringing product.
AstraZeneca AB v. Apotex Corp.
PDF, Size: 207 KB
See Also
Federal Circuit Weighs Use of EMVR in Pharmaceutical Case
Federal Circuit affirms award of 50% of gross margin, finding that, even though the entire market value rule is not per se inapplicable in the pharmaceutical context, it does not apply in this case because patents cover the entire infringing product.